India’s leading pharma packaging company, SCHOTT KAISHA, has completed half a decade of successful partnership. Since its formation in 2008, this 50:50 joint venture achieved consistent growth at an average of 25 percent every year. Currently, SCHOTT KAISHA employs approximately 1,600 people in its plants in Daman and Jambusar and its Mumbai office and supplies primary packaging material, like vials and ampoules, to many leading pharmaceutical companies in India. "We are happy to have met highest demands of quality and supply with maximum customer satisfaction. We remain committed to help our customers achieve their own growth and quality objectives in India as well as abroad. This motivates the SCHOTT KAISHA family to strive for the next milestones," says Kairus Dadachanji, Managing Director of SCHOTT KAISHA.
The SCHOTT KAISHA partnership began in 2008, when Kaisha Manufactures Pvt. Ltd., an Indian producer of pharmaceutical containers made of neutral glass, joined hands with the international technology group SCHOTT, a manufacturer of premium pharma packaging with headquarters in Germany. Today, SCHOTT KAISHA is a leading supplier for glass primary packaging to the pharmaceutical industry offering a "one stop shop" solution for the entire range of small volume tubular glass packaging: ampoules, vials, cartridges and sterile prefillable syringes in India and the neighbouring South Asian region.
Building on its success, the company inaugurated India’s first fully automated pharmaceutical packaging plant in February 2013 in Jambusar, Gujarat. This Greenfield facility, set up with an initial investment of 20 million Euros (136 crores INR), helped SCHOTT KAISHA to increase its production capacity by almost 50 percent to around 2.4 billion pieces per year. With the first module nearing its full capacity by Jan 2014, the company is looking to further expand more than 1700. The facility is housed in an area of 20 acres with ample room to construct additional production modules in parallel with the increasing demand of customers.
One of the main distinguishing factors of SCHOTT KAISHA is the systems and quality norms that fall in line with international regulatory and technologies that satisfy the rising customer demands. "Due to our strong focus on quality, based on SCHOTT’s more than one hundred years of experience, we retain state of the art equipment and a highly skilled workforce dedicated to quality control and inspection. Maintaining consistent global standards in all our facilities worldwide helps us to offer tailor-made products and services for growing international pharmaceutical markets such as India," says Dr. Jürgen Sackhoff, Executive Vice President of SCHOTT Pharmaceutical Systems.
In the last five years, SCHOTT KAISHA has been awarded ISO 9001, ISO 14000-18000 and ISO 15378 certificates. In addition, SCHOTT KAISHA has successfully set up an independent tool room with highly specialized Computer Numerical Machines (CNC) that enable a even more precise dimensional control.
The rapidly evolving Indian pharmaceutical industry creates a challenging yet an exciting opportunity for SCHOTT KAISHA. According to several studies, the pharmaceutical market (drug spending) in India is expanding by approximately 14 to 17 percent per year, which is primarily driven by demand from India’s prospering middle class. To cater to this steady growth in demand, SCHOTT KAISHA plans to extend its capacity by building further manufacturing lines in Jambusar. "We are confident of exceeding the market growth rate also in the future," concludes Kairus Dadachanji.